Waltham, MA

Massachusetts Eye Research and Surgery Institution

Post-Acute COVID-19 Syndrome

Tonabersat

Inflammx Therapeutics Inc

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The primary objective of this study is to evaluate the safety and efficacy of Xiflam versus Placebo in patients who present with signs and symptoms of Long COVID.

Xiflam (n=10) or placebo (n=5) will be administered orally once a day (QD) for 12 weeks.

Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)

Massachusetts Eye Research and Surgery Institution | Waltham, MA

Site insights

Work at this site?

Active trials

Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)

Trial sponsors